Trial Profile
An Open Label, Non-Comparative, Phase II Study of ZD1839 (Iressa) as First-Line Treatment in Subjects With Relapsed Prostate Cancer Following Radical Prostatectomy or Radiotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 05 Jun 2009 New trial record.